Why RDHL Stock dropped -6.91% Today — RQD Quant Desk Flash

The Roarable RQD rating assigns RDHL a score of 52 out of 100, a letter grade of D+, and a verdict label of "Roarable Sell — Weak Fundamentals / Trim" (per the Roarable RQD rating). The five pillars, each scored out of 20, are:

• Fundamental Cash Engine: 12 / 20 — the rating cites ROIC of 0% and FCF yield of 0%. For a prospective investor, the absence of measurable return on capital and free-cash generation means the stock's value cannot currently be anchored to earnings or cash flow.
• Whale 13F Flow: 10 / 20 — reflects institutional accumulation and options positioning. A sub-half score indicates limited evidence of conviction from large institutional holders.
• Insider Conviction: 9 / 20 — reflects SEC Form 4 and Congressional PTR cluster flow. This is the second-weakest pillar, signaling little visible insider buying conviction.
• Macro Regime Fit: 8 / 20 — the rating cites Beta of 1.0 and sector sensitivity. The lowest-scoring pillar suggests the stock's regime fit is poor relative to the framework's criteria.
• Forensic Balance Sheet: 13 / 20 — cites Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5. This is the strongest pillar, indicating the balance-sheet picture is comparatively less weak than the earnings and flow signals.

Translated into investor implications: the rating's upside case rests mainly on the balance-sheet pillar and on whatever catalyst flow emerges; the valuation tradeoff is that the cash-engine and flow pillars are weak, so the stock offers little fundamental earnings support at the current price. The overall grade signals caution and a "trim" stance rather than accumulation, and this is an educational reading of the framework, not personalized advice.

• NCI grant (RISK WATCH, RED light): A $2.9 million NCI grant was reported for clinical development of the opaganib and CAR T-cell combination in ultra-high-risk multiple myeloma (per the news feed, "PR Newswire"). This is flagged as a risk-watch item in the feed.
• Drug rights return (MARKET WIRE): Drug rights are reported to return to RedHill as Hyloris agrees to a $200,000 break-up fee (per the news feed, "Stock Titan").
• Price pressure (MARKET WIRE): A "Symmetrical Triangle" headline reports the shares pressured near $0.42 as they test lower support (per the news feed, "siam.in").
• Other MARKET WIRE items: A depositary-share ratio headline (10,000 ordinary shares per depositary share), a Benzinga pre-market mover mention, and a Yahoo Finance seasonal-returns item.

Per the Butterfly Supply-Chain Graph, the supply_chain is "NONE," with no butterfly links and no proprietary signals.

• What are RDHL's reported revenues, earnings, cash, and debt across periods, given the financials section is empty?
• What is the analyst consensus rating and price target, given the analyst data section is empty?
• Who are the institutional (13F) and insider (Form 4) holders, and what is their recent activity?
• What is the status and commercial prospect of the opaganib program, and how material is the $200,000 break-up fee relative to the company's size?
• What is the basis for the stated $3.7M market capitalization, and how does it reconcile with the Altman and Piotroski readings?